<SEC-DOCUMENT>0001140361-25-005770.txt : 20250225
<SEC-HEADER>0001140361-25-005770.hdr.sgml : 20250225
<ACCEPTANCE-DATETIME>20250225071933
ACCESSION NUMBER:		0001140361-25-005770
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250225
DATE AS OF CHANGE:		20250225

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arbutus Biopharma Corp
		CENTRAL INDEX KEY:			0001447028
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				980597776
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-85963
		FILM NUMBER:		25659394

	BUSINESS ADDRESS:	
		STREET 1:		701 VETERANS CIRCLE
		CITY:			WARMINSTER
		STATE:			PA
		ZIP:			18974
		BUSINESS PHONE:		604-419-3200

	MAIL ADDRESS:	
		STREET 1:		701 VETERANS CIRCLE
		CITY:			WARMINSTER
		STATE:			PA
		ZIP:			18974

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKMIRA PHARMACEUTICALS Corp
		DATE OF NAME CHANGE:	20110607

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKMIRA PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20081003

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Roivant Sciences Ltd.
		CENTRAL INDEX KEY:			0001635088
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				981173944
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		CLARENDON HOUSE, 2 CHURCH STREET
		CITY:			HAMILTON HM11
		STATE:			D0
		ZIP:			HM11
		BUSINESS PHONE:		441-295-5950

	MAIL ADDRESS:	
		STREET 1:		CLARENDON HOUSE
		STREET 2:		2 CHURCH STREET
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM11
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13D/A</submissionType>
<previousAccessionNumber>0001144204-15-016451</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001635088</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>13</amendmentNo>
<securitiesClassTitle>Common Shares, without par value</securitiesClassTitle>
<dateOfEvent>02/21/2025</dateOfEvent>
<previouslyFiledFlag>false</previouslyFiledFlag>
<issuerInfo>
<issuerCIK>0001447028</issuerCIK>
<issuerCUSIP>03879J100</issuerCUSIP>
<issuerName>Arbutus Biopharma Corp</issuerName>
<address>
<com:street1>701 Veterans Circle</com:street1>
<com:city>Warminster</com:city>
<com:stateOrCountry>PA</com:stateOrCountry>
<com:zipCode>18974</com:zipCode>
</address>
</issuerInfo>
<authorizedPersons>
<notificationInfo>
<personName>Derek J. Dostal</personName>
<personPhoneNum>(212) 450-4000</personPhoneNum>
<personAddress>
<com:street1>Davis Polk &amp; Wardwell LLP</com:street1>
<com:street2>450 Lexington Ave</com:street2>
<com:city>New York</com:city>
<com:stateOrCountry>NY</com:stateOrCountry>
<com:zipCode>10017</com:zipCode>
</personAddress>
</notificationInfo>
</authorizedPersons>
</coverPageHeader>
<reportingPersons>
<reportingPersonInfo>
<reportingPersonCIK>0001635088</reportingPersonCIK>
<reportingPersonName>Roivant Sciences Ltd.</reportingPersonName>
<fundType>OO</fundType>
<citizenshipOrOrganization>D0</citizenshipOrOrganization>
<soleVotingPower>38847462</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>38847462</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
<aggregateAmountOwned>38847462</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>20.5</percentOfClass>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<commentContent>As of the date of this Amendment No. 13 to the Schedule 13D, Roivant Sciences Ltd. ("Roivant") beneficially owns 38,847,462 common shares, without par value ("Common Shares"), of Arbutus Biopharma Corporation (the "Issuer"). The percentage of outstanding Common Shares that may be deemed to be beneficially owned by Roivant is calculated based on an aggregate of 189,963,492 Common Shares issued and outstanding as of December 31, 2024, based on information provided by the Issuer.</commentContent>
</reportingPersonInfo>
</reportingPersons>
<items1To7>
<item1>
<securityTitle>Common Shares, without par value</securityTitle>
<issuerName>Arbutus Biopharma Corp</issuerName>
<issuerPrincipalAddress>
<com:street1>701 Veterans Circle</com:street1>
<com:city>Warminster</com:city>
<com:stateOrCountry>PA</com:stateOrCountry>
<com:zipCode>18974</com:zipCode>
</issuerPrincipalAddress>
<commentText>EXPLANATORY NOTE&#13;
&#13;
Pursuant to Rule 13d-2 of the Securities Exchange Act of 1934, as amended, this Amendment No. 13 ("Amendment No. 13") amends certain items of the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on March 16, 2015, as amended by Amendments No. 1 through 12, previously filed with the SEC (the "Schedule 13D") relating to the Common Shares, without par value (the "Common Shares"), of Arbutus Biopharma Corporation (the "Issuer"), which are beneficially owned by Roivant Sciences Ltd. ("Roivant" or the "Reporting Person"). This Amendment No. 13 amends the Original Schedule 13D on behalf of the Reporting Person to furnish the information set forth herein. Except as set forth below, all Items of the Original Schedule 13D remain unchanged. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule 13D.</commentText>
</item1>
<item2>
<filingPersonName>Item 2 is hereby amended solely to restate the list of Covered Persons in Item 2(a) of the Schedule 13D with those listed on Exhibit 99.1 hereto, which Exhibit 99.1 is incorporated into this Item 2 by reference.</filingPersonName>
</item2>
<item4>
<transactionPurpose>Item 4 is hereby amended by adding the following to the end thereof:&#13;
&#13;
On February 21, 2025, Roivant's Chief Executive Officer, Matthew Gline, met with the Board of Directors of the Issuer and requested that each of the members of the Board of Directors resign from their position as a director of the Issuer. As announced by the Issuer, each member of the Issuer's Board of Directors agreed to the request and resigned on February 24, 2025. In conjunction with their resignations, the Board of Directors agreed to (i) reduce the number of directors from seven to five; and (ii) replace the Issuer's Board of Directors with five individuals - Lindsay Androski, Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija - to serve until the 2025 Annual General Meeting of Shareholders or until their respective successors are duly elected or appointed. In addition, as disclosed by the Issuer, the Board of Directors has appointed Ms. Androski to serve as President and Chief Executive Officer of the Issuer. Ms. Androski, along with Mr. Gline and Mr. Bishop, are employees of Roivant Sciences, Inc., a wholly-owned subsidiary of Roivant.</transactionPurpose>
</item4>
<item5>
<percentageOfClassSecurities>Reporting Person (Roivant)&#13;
&#13;
Roivant beneficially owns 38,847,462, or 20.5%, of the Common Shares and has sole voting and dispositive power over such Common Shares. Roivant disclaims beneficial ownership in all Common Shares reported herein, except to the extent of Roivant's respective pecuniary interest therein.</percentageOfClassSecurities>
<numberOfShares>See rows 7-10 of the cover page to this Amendment No. 13 for information regarding Roivant's power to vote or direct the vote and its power to dispose or direct the disposition of the Common Shares. Except as disclosed in this Schedule 13D, Roivant does not and, to Roivant's knowledge, the Covered Persons do not beneficially own any Common Shares or have the right to acquire any Common Shares.</numberOfShares>
<transactionDesc>Except as disclosed in this Amendment No. 13, Roivant has not effected and, to Roivant's knowledge, none of the Covered Persons has effected any transactions in the Common Shares since the last Schedule 13D/A was filed with the SEC on February 18, 2025.</transactionDesc>
<listOfShareholders>Except as disclosed in this Amendment No. 13, no person other than Roivant has the right to receive, or the power to direct the receipt of dividends from, the proceeds from the sale of the shares to which this Amendment No. 13 relates.</listOfShareholders>
<date5PercentOwnership>Not applicable.</date5PercentOwnership>
</item5>
<item7>
<filedExhibits>Exhibit 99.1 - Covered Persons</filedExhibits>
</item7>
</items1To7>
<signatureInfo>
<signaturePerson>
<signatureReportingPerson>Roivant Sciences Ltd.</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Keyur Parekh</signature>
<title>Keyur Parekh, Authorized Signatory</title>
<date>02/25/2025</date>
</signatureDetails>
</signaturePerson>
</signatureInfo>
</formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20044253_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.1.1.5279
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div>
        <div style="text-align: right; font-weight: bold;">Exhibit 99.1</div>
        <div>&#160;</div>
        <div style="font-style: italic; font-weight: bold;">Covered Persons</div>
        <div><br>
        </div>
        <div>Roivant has a board of directors (such individuals, collectively, the "<font style="font-weight: bold;">Covered Persons</font>"). The name, present principal occupation and country of citizenship of each of the Covered Persons is set forth
          below, along with the principal business address of the employer of each of the Covered Persons.</div>
      </div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" id="ze6eb5d01f07f4436bc94d17038e9c435" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 22%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">Name</div>
              </td>
              <td colspan="1" style="width: 2%; padding-bottom: 2px;">&#160;</td>
              <td style="width: 25%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">Principal Business</div>
                <div style="text-align: center; font-weight: bold;">Address of Employer</div>
              </td>
              <td colspan="1" style="width: 2%; padding-bottom: 2px;">&#160;</td>
              <td style="width: 24%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">Present Principal Occupation</div>
              </td>
              <td colspan="1" style="width: 2%; padding-bottom: 2px;">&#160;</td>
              <td style="width: 23%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">Citizenship</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%;">&#160;</td>
              <td rowspan="1" style="width: 25%;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%;">&#160;</td>
              <td rowspan="1" style="width: 24%;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%;">&#160;</td>
              <td rowspan="1" style="width: 23%;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 22%; text-align: left; vertical-align: top;">Matthew Gline<br>
              </td>
              <td colspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td style="width: 25%; text-align: left; vertical-align: top;">
                <div>c/o Roivant Sciences Ltd., 7th Floor, 50 Broadway</div>
                <div>London SW1H 0DB United Kingdom</div>
              </td>
              <td colspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td style="width: 24%; text-align: left; vertical-align: top;">
                <div>Director and Principal Executive Officer, Roivant Sciences Ltd.&#894; Chief Executive Officer, Roivant Sciences, Inc.</div>
              </td>
              <td colspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td style="width: 23%; text-align: left; vertical-align: top;">
                <div>United States</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;"><br>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;"><br>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;"><br>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;"><br>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;">
                <div>Keith Manchester</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;">
                <div>888 Seventh Avenue, 43rd Floor, New York, NY 10106</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;">
                <div>Partner and the Head of Life Sciences, QVT Financial LP</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;">
                <div>United States</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;"><br>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;"><br>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;"><br>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;"><br>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;">
                <div>Melissa Epperly</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;">
                <div>c/o Roivant Sciences Ltd., 7th Floor, 50 Broadway</div>
                <div>London SW1H 0DB United Kingdom</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;">
                <div>Healthcare Executive</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;">
                <div>United States</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;"><br>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;"><br>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;">
                <div>Daniel Gold</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;">
                <div>888 Seventh Avenue, 43rd Floor, New York, NY 10106</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;">
                <div>Founder and Chief Executive Officer of QVT Financial LP</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;">
                <div>United States</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;"><br>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;"><br>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;">
                <div>Meghan FitzGerald</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;">
                <div>c/o Roivant Sciences Ltd., 7th Floor, 50 Broadway</div>
                <div>London SW1H 0DB United Kingdom</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;">
                <div>Director, Tenet Healthcare&#894; Founder, K2HealthVentures&#894; Adjunct Professor of Health Policy at Columbia University</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;">
                <div>United States</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;"><br>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;"><br>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;">
                <div>James C. Momtazee</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;">
                <div>2884 Sand Hill Rd #100, Menlo Park, CA 94025</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;">
                <div>Managing Partner, Patient Square Capital</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;">
                <div>United States</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;"><br>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;"><br>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;">
                <div>Ilan Oren</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;">
                <div>1 Dexcel Street, Or Akiva, 3060000, Israel</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;">
                <div>Co-Chief Executive Officer, Dexcel Pharma</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;">
                <div>Israel</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 22%; text-align: left; vertical-align: top;">
                <div>Mayukh Sukhatme</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 25%; text-align: left; vertical-align: top;">
                <div>c/o Roivant Sciences Ltd., 7th Floor, 50 Broadway</div>
                <div>London SW1H 0DB United Kingdom</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 24%; text-align: left; vertical-align: top;">
                <div>Director, Roivant Sciences Ltd.&#894; President and Chief Investment Officer, Roivant Sciences, Inc.</div>
              </td>
              <td colspan="1" rowspan="1" style="width: 2%; text-align: left; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 23%; text-align: left; vertical-align: top;">
                <div>United States</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
